Journal of Neuroendocrinology

GLP-1 receptor agonists, metabolic syndrome, and Alzheimer's disease: Lessons and opportunities from the EVOKE trials

By Gupta Pragati, Valeria Pozzilli, Anastasia De Giovanni, Paolo Pozzilli

ReviewInterventions

The paper

Gupta Pragati, Valeria Pozzilli, Anastasia De Giovanni, Paolo Pozzilli

Queen Mary University of London; Università Campus Bio-Medico

Journal of Neuroendocrinology, 1 Aug 2026

doi.org/10.1111/jne.70246 PubMed 42580680

Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Drug Design, Development and Therapy5 Oct 2026
GLP-1 agonists linked to lower dementia risk after COVID-19
Neurology Genetics4 Oct 2026
GLP-1 receptor agonists link to lower stroke and Alzheimer risk
Alzheimer's & Dementia7 Oct 2026
Brain receptor gene activity linked to lower Alzheimer’s risk